Orbimed Advisors LLC Insmed Inc Transaction History

Orbimed Advisors LLC

$3.21 Billion
Q1 2025

A detailed history of Orbimed Advisors LLC transactions in Insmed Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 28,659 shares of INSM stock, worth $2.88 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

28,659

Previous 94,559 69.69%

Holding current value

$2.88 Million

Previous $6.53 Million 66.51%

% of portfolio

0.07%

Previous 0.18%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$65.25 - $83.83 $4.3 Million - $5.52 Million	-65,900 Reduced 69.69%	28,659 $2.19 Million
Q4 2024 Feb 14, 2025	BUY	$66.29 - $76.63 $6.27 Million - $7.25 Million	94,559 New	94,559 $6.53 Million
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $804,170 - $2 Million	-59,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $8.11 Million - $12.6 Million	-503,300 Reduced 89.51%	59,000 $1.41 Million
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $8.71 Million - $14.5 Million	562,300 New	562,300 $9.92 Million
Q4 2018 Feb 14, 2019	SELL	$11.6 - $18.7 $21.2 Million - $34.2 Million	-1,829,300 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$18.95 - $28.08 $20.8 Million - $30.8 Million	-1,098,591 Reduced 37.52%	1,829,300 $37 Million
Q1 2018 May 15, 2018	BUY	$21.69 - $32.99 $31 Million - $47.2 Million	1,431,100 Added 95.61%	2,927,891 $65.9 Million
Q4 2017 Feb 14, 2018	SELL	$26.43 - $31.78 $10 Million - $12 Million	-378,225 Reduced 20.17%	1,496,791 $46.7 Million
Q3 2017 Nov 14, 2017	BUY	$11.61 - $31.21 $21.8 Million - $58.5 Million	1,875,016	1,875,016 $58.5 Million

Others Institutions Holding INSM

# of Institutions

489

Shares Held

197M

Call Options Held

892K

Put Options Held

1.77M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $13.6B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account

Orbimed Advisors LLC Insmed Inc Transaction History